PRNewswire: August 22, 2017 – SAN JOSE, CA, U.S.A. – Teikoku Pharma USA, Inc. (Teikoku Pharma) today announced positive topline results from its phase 2 proof of concept study of TPU-006, a 3-day dexmedetomidine transdermal patch, a novel drug delivery system with a nonopioid active moiety for the…
